InvestorsHub Logo
Followers 35
Posts 6308
Boards Moderated 0
Alias Born 02/09/2015

Re: biodoc post# 151687

Wednesday, 06/15/2016 11:56:00 PM

Wednesday, June 15, 2016 11:56:00 PM

Post# of 403773
Very very helpful data, about rates of remission without treatment, to provide some sense of the lay of the land. For sure they would need good data to move forward, and one can only hope.

Let's say it does not work out- why are they so set on this after all? What data do they have that we do not know? I am in the midst of sitting down at the day's end to read every bit of info I can find about B and distal colitis, call it what you will. Will look back at PMX when I get the chance- soon, now

But even so, Leo said that he would move forward if data fr B-OM looked good. Not just no side effects but some postive indications. So B-OM must be showing some benefit, right? Is this too much to presume?

And they hire Sonis?

And they hire Farraye?

So even worst case B-UP is a flop it means B-OM must look ok, and there are still many possibilities for other B uses, sorry to be repetitive, conjunctivitis, blepharitis, HS.

Just starting to look back at all the B-UP stuff I get right into 3/30/6 B-UP to go ahead- country unnamed-and Jorgensen out. And then 1/26/15 B-UP look good, and by the way, ctix moving forward with plns to uplist on NASDAQ-sigh.....

One finds oneself right back in annoying waters, or mud, maybe more accurately, with just the very start of the search, to learn all there is to know about Brilacidin and ulcerative colitis(distal).

And yet I will read on undeterred, as many of you are no doubt also doing even now.